[1]
|
Zhang, X., Liu, S., Liu, Y., et al. (2017) Economic Burden for Lung Cancer Survivors in Urban China. International Journal of Environmental Research and Public Health, 14, 308. https://doi.org/10.3390/ijerph14030308
|
[2]
|
Barnfield, P.C. and Ellis, P.M. (2016) Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations. Drugs, 76, 1321-1336.
https://doi.org/10.1007/s40265-016-0628-6
|
[3]
|
Ramalingam, S. and Belani, C. (2008) Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions. Oncologist, 13, 5-13. https://doi.org/10.1634/theoncologist.13-S1-5
|
[4]
|
Schiller, J.H., Harrington, D., Belani, C.P., et al. (2002) Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 346, 92-98.
https://doi.org/10.1056/NEJMoa011954
|
[5]
|
Greenhalgh, J., Dwan, K., Boland, A., et al. (2016) First-Line Treatment of Advanced Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Squamous Non-Small Cell Lung Cancer. Cochrane Database of Systematic Reviews, 5, CD010383. https://doi.org/10.1002/14651858.CD010383.pub2
|
[6]
|
Shi, Y., Zhang, L., Liu, X., et al. (2013) Icotinib versus Gefitinib in Previously Treated Advanced Non-Small-Cell Lung Cancer (ICOGEN): A Randomised, Double-Blind Phase 3 Non-Inferiority Trial. Lancet Oncology, 14, 953-961.
https://doi.org/10.1016/S1470-2045(13)70355-3
|
[7]
|
Li, L., Han, R., Xiao, H., et al. (2014) Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells in Vitro and in Vivo through Inhibition of IL-6 Signaling and EMT Reversal. Clinical Cancer Research, 20, 2714-2726.
https://doi.org/10.1158/1078-0432.CCR-13-2613
|
[8]
|
Li, J. and Wang, X.H. (2020) Combined Treatment with N-Acetylcysteine and Gefitinib Overcomes Drug Resistance to Gefitinib in NSCLC Cell Line. Cancer Medicine, 9, 1495-1502. https://doi.org/10.1002/cam4.2610
|
[9]
|
Zhang, Y., Lv, C., Dong, Y., et al. (2020) Aspirin-Targeted PD-L1 in Lung Cancer Growth Inhibition. Thoracic Cancer, 11, 1587-1593.
|
[10]
|
Chuang, S.-E. (2013) Aspirin Antagonizes the Cytotoxic Effect of Methotrexate in Lung Cancer Cells. Oncology Reports, 30, 1497-1505. https://doi.org/10.3892/or.2013.2561
|
[11]
|
Andrews, P., Thyssen, J. and Lorke, D. (1982) The Biology and Toxicology of Molluscicides, Bayluscide. Pharmacology & Therapeutics, 19, 245-295. https://doi.org/10.1016/0163-7258(82)90064-X
|
[12]
|
Al-Hadiya, B.M.H. (2005) Niclosamide: Comprehensive Profile. Profiles of Drug Substances, Excipients and Related Methodology, 32, 67-96. https://doi.org/10.1016/S0099-5428(05)32002-8
|
[13]
|
Jin, Y., Lu, Z., Ding, K., et al. (2010) Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF-kB Pathway and Generation of Reactive Oxygen Species. Cancer Research, 70, 2516-2527. https://doi.org/10.1158/0008-5472.CAN-09-3950
|
[14]
|
Osada, T., Chen, M., Yang, X.Y., et al. (2011) Antihelminth Compound Niclosamide Downreguates WNT Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations. Cancer Research, 71, 4172-4182.
https://doi.org/10.1158/0008-5472.CAN-10-3978
|
[15]
|
Sack, U., Walther, W., Scudiero, D., et al. (2011) Novel Effect of Antihelminthic Niclosamide on S100A4-Mediated Metastatic Progression in Colon Cancer. Journal of the National Cancer Institute, 103, 1018-1036.
https://doi.org/10.1093/jnci/djr190
|
[16]
|
Ren, X., Duan, L., He, Q., et al. (2010) Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Medicinal Chemistry Letters, 1, 454-459. https://doi.org/10.1021/ml100146z
|
[17]
|
Liu, Z., Li, Y., Lv, C., et al. (2016) Anthelmintic Drug Niclosamide Enhances the Sensitivity of Chronic Myeloid Leukemia Cells to Dasatinib through Inhibiting Erk/Mnk1/eIF4E Pathway. Biochemical and Biophysical Research Communications, 478, 893-899. https://doi.org/10.1016/j.bbrc.2016.08.047
|
[18]
|
Arend, R.C., Londoño-Joshi, A.I., Samant, R.S., et al. (2014) Inhibition of Wnt/β-Catenin Pathway by Niclosamide: A Therapeutic Target for Ovarian Cancer. Gynecologic Oncology, 134, 112-120.
https://doi.org/10.1016/j.ygyno.2014.04.005
|
[19]
|
Park, S.J., Shin, J.H., Kang, H., et al. (2011) Niclosamide Induces Mitochondria Fragmentation and Promotes Both Apoptotic and Autophagic Cell Death. BMB Reports, 44, 517-522. https://doi.org/10.5483/BMBRep.2011.44.8.517
|
[20]
|
Li, R., Hu, Z., Sun, S.Y., et al. (2013) Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-Small Cell Lung Cancer. Molecular Cancer Therapeutics, 12, 2200-2212.
https://doi.org/10.1158/1535-7163.MCT-13-0095
|
[21]
|
Li, R., You, S., Hu, Z., et al. (2013) Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer. PLoS One, 8, e74670. https://doi.org/10.1371/journal.pone.0074670
|
[22]
|
Li, Y., Li, P.K., Roberts, M.J., et al. (2014) Multi-Targeted Therapy of Cancer by Niclosamide: A New Application for an Old Drug. Cancer Letters, 349, 8-14. https://doi.org/10.1016/j.canlet.2014.04.003
|
[23]
|
Yo, Y.-T., Lin, Y.-W., Wang, Y.-C., et al. (2012) Growth Inhibition of Ovarian Tumor-Initiating Cells by Niclosamide. Molecular Cancer Therapeutics, 11, 1703-1712. https://doi.org/10.1158/1535-7163.MCT-12-0002
|
[24]
|
Liu, J., Chen, X., Ward, T., et al. (2016) Combined Niclosamide with Cisplatin Inhibits Epithelial Mesenchymal Transition and Tumor Growth in Cisplatin-Resistant Triple-Negative Breast Cancer. Tumor Biology, 37, 9825-9835.
https://doi.org/10.1007/s13277-015-4650-1
|
[25]
|
Wang, Y.-C., Chao, T.-K., Chang, C.-C., et al. (2013) Drug Screening Identifies Niclosamide as an Inhibitor of Breast Cancer Stem-Like Cells. PLoS One, 8, e74538. https://doi.org/10.1371/journal.pone.0074538
|
[26]
|
Chen, B., Wei, W., Ma, L., et al. (2017) Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells in Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Gastroenterology, 152, 2022-2036. https://doi.org/10.1053/j.gastro.2017.02.039
|
[27]
|
Lee, M.-C., Chen, Y.-K., Hsu, Y.-J., et al. (2020) Niclosamide Inhibits the Cell Proliferation and Enhances the Responsiveness of Esophageal Cancer Cells to Chemotherapeutic Agents. Oncology Reports, 43, 549-561.
|
[28]
|
Chang, X., Zhen, X., Liu, J., et al. (2017) The Antihelmenthic Phosphate Niclosamide Impedes Renal Fibrosis by Inhibiting Homeodomain-Interacting Protein Kinase 2 Expression. Kidney International, 92, 612-624.
https://doi.org/10.1016/j.kint.2017.01.018
|
[29]
|
Kim, M.-O., Choe, M.H., Yoon, Y.N., et al. (2017) Antihelminthic Drug Niclosamide Inhibits CIP2A and Reactivates Tumor Suppressor Protein Phosphatase 2A in Non-Small Cell Lung Cancer Cells. Biochemical Pharmacology, 144, 78-89. https://doi.org/10.1016/j.bcp.2017.08.009
|
[30]
|
Gahr, S., Stoehr, R., Geissinger, E., et al. (2013) EGFR Mutational Status in a Large Series of Caucasian European NSCLC Patients: Data from Daily Practice. British Journal of Cancer, 109, 1821-1828.
https://doi.org/10.1038/bjc.2013.511
|
[31]
|
Lee, M.C., Chen, Y.K., Hsu, Y.J., et al. (2020) Niclosamide Inhibits the CELL proliferation and Enhances the Responsiveness of Esophageal Cancer Cells to Chemotherapeutic Agents. Oncology Reports, 43, 549-561.
https://doi.org/10.3892/or.2019.7449
|
[32]
|
Pan, J.-X., Ding, K. and Wang, C.-Y. (2012) Niclosamide, an Old Antihelminthic Agent, Demonstrates Antitumor Activity by Blocking Multiple Signaling Pathways of Cancer Stem Cells. Chinese Journal of Cancer, 31, 178-184.
https://doi.org/10.5732/cjc.011.10290
|
[33]
|
Chen, W., Mook Jr., R.A., Premont, R.T. and Wang, J.B. (2018) Niclosamide: Beyond an Antihelminthic Drug. Cellular Signalling, 41, 89-96. https://doi.org/10.1016/j.cellsig.2017.04.001
|
[34]
|
You, S., Li, R., Park, D., et al. (2014) Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer. Molecular Cancer Therapeutics, 13, 606-616. https://doi.org/10.1158/1535-7163.MCT-13-0608
|
[35]
|
Chai, W.-H., Li, Y.-R., Lin, S.-H., et al. (2020) In Vitro Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells and. Anticancer Research, 40, 1405-1417.
https://doi.org/10.21873/anticanres.14082
|
[36]
|
左瑜芳, 杨东雁, 徐祖敏, 等. 氯硝柳胺对肺癌细胞株顺铂敏感性的影响[J]. 广东医科大学学报, 2017, 35(2): 144-147.
|
[37]
|
Zuo, Y., Yang, D., Yu, Y., et al. (2018) Niclosamide Enhances the Cytotoxic Effect of Cisplatin in Cisplatin-Resistant Human Lung Cancer Cells via Suppression of Lung Resistance-Related Protein and c-myc. Molecular Medicine Reports, 17, 3497-3502.
|
[38]
|
Helfman, D.M., Kim, E.J., Lukanidin, E. and Grigorian, M. (2005) The Metastasis Associated Protein S100A4: Role in Tumour Progression and Metastasis. British Journal of Cancer, 92, 1955-1958. https://doi.org/10.1038/sj.bjc.6602613
|